Tuberculosis (TB) Diagnostics Market to Reach USD 4.93 Billion by 2034

The Global Tuberculosis Diagnostics Market is expanding steadily as healthcare systems strengthen early detection and disease-control efforts. According to Exactitude Consultancy, the market, valued at USD 3.12 billion in 2024, is projected to reach USD 4.93 billion by 2034, registering a CAGR of 4.6 % from 2025 to 2034.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/48300

The surge is fueled by the increasing prevalence of drug-resistant tuberculosis, the integration of rapid molecular and imaging tools, and international funding aimed at achieving the WHO's "End TB Strategy."

Key Takeaways
• Market Size: USD 3.12 billion (2024) → USD 4.93 billion (2034)
• CAGR: 4.6 % (2025-2034)
• Dominant Segment: Molecular Diagnostics (Xpert MTB/RIF & Truenat systems)
• Emerging Technologies: AI-based Chest X-ray Analytics & Biosensor Platforms
• Regional Leaders: Asia-Pacific leads global testing volume; Africa shows fastest public-health investment growth

Market Story
Tuberculosis remains one of the world's deadliest infectious diseases, with more than 10 million new cases annually. Rapid and accurate diagnosis is crucial to reducing transmission and enabling effective treatment. The market is now undergoing a technological shift from conventional sputum smear microscopy to molecular assay-based testing, digital radiology, and AI-assisted screening.

Major developing countries are deploying portable GeneXpert systems, Truenat point-of-care devices, and LAM antigen tests to expand diagnostic reach in rural regions. Simultaneously, automation and data connectivity are enhancing national TB control programs, allowing real-time case tracking and treatment monitoring.

Support from organizations such as the Global Fund, WHO, and USAID continues to boost testing capacities in high-burden countries like India, Indonesia, South Africa, and Nigeria.

Segmentation Overview
By Test Type
• Smear Microscopy (Traditional & LED Fluorescent)
• Culture Based Testing (Liquid & Solid Culture Media)
• Molecular Diagnostics (PCR, GeneXpert, Line Probe Assay, Truenat)
• Radiographic Examination (Digital X-ray, AI Image Analysis)
• Serological & Immunoassay Tests (ELISA, IGRA Tests)
• Others (Biosensors, Nanotech Diagnostics)

By End User
• Hospitals & Reference Laboratories
• Diagnostic Centers
• Public Health Programs & NGOs
• Research & Academic Institutes

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/48300/tuberculosis-diagnostics-market

Recent Developments
• Cepheid Inc. received expanded WHO prequalification for its next-generation GeneXpert Edge system, supporting multi-drug resistance testing at point of care.
• Molbio Diagnostics (India) scaled production of Truenat MTB and MTB-RIF Dx kits for national TB programs in Asia and Africa.
• F. Hoffmann-La Roche Ltd. and Qiagen N.V. launched high-sensitivity PCR platforms integrated with cloud-based data systems.
• Fujifilm Healthcare introduced AI-driven digital radiography for mass screening campaigns.
• Abbott Laboratories and Becton Dickinson (BD) are developing portable biosensor TB diagnostic devices for low-resource settings.

Expert Quote
"Tuberculosis diagnostics are entering a new era of accessibility and speed. Integration of molecular testing with AI screening is enabling countries to detect and treat cases faster than ever before,"
said Irfan Tamboli, Business Development Executive at Exactitude Consultancy.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=48300

Market Drivers
• Global initiatives such as the WHO End TB Strategy and national eradication targets
• Increasing incidence of multi-drug resistant tuberculosis (MDR-TB)
• Rapid adoption of molecular and AI-based diagnostic tools
• Growth of public-private partnerships in developing countries
• Rising investment in mobile and point-of-care testing solutions

Forecast and Outlook
The TB diagnostics market will continue to grow as countries accelerate early-detection strategies and expand access to molecular testing. Over the next decade, AI-assisted radiology and portable PCR devices will complement traditional laboratory tests to reach remote populations.

By 2034, automated networked systems and digital reporting tools will enable real-time surveillance, supporting global efforts to cut TB mortality rates by 90 %. Partnerships between tech firms and health ministries will play a crucial role in this transformation.

Regional Insights
• Asia-Pacific: Largest testing volume driven by India and China's national programs; deployment of portable PCR systems in rural zones.
• Africa: Fastest growth due to international funding and increasing urban screening centers.
• North America: Focus on latent TB testing and immigrant screening programs.
• Europe: Strong policy framework and investment in drug-resistance surveillance.
• Latin America: Expanding lab network support from PAHO and regional governments.

Conclusion
The Global Tuberculosis Diagnostics Market is evolving into a digitally connected, rapid-response ecosystem. As governments and industry collaborate to meet WHO eradication goals, the integration of AI, molecular testing, and data analytics will reshape the future of TB control.

Companies focusing on affordable, portable, and cloud-enabled solutions will be the key contributors to global elimination efforts.

This report is also available in the following languages : Japanese (結核診断), Korean (결핵 진단), Chinese (结核病诊断), French (Diagnostic de la tuberculose), German (Tuberkulosediagnostik), and Italian (Diagnostica della tubercolosi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/48300/tuberculosis-diagnostics-market#request-a-sample

Related Reports
Multidrug Resistant Tuberculosis Market
https://exactitudeconsultancy.com/reports/72907/multidrug-resistant-tuberculosis-market

Pulmonary Tuberculosis Clinical Market
https://exactitudeconsultancy.com/reports/73650/pulmonary-tuberculosis-clinical-market

Mycobacterium Tuberculosis PCR Detection Kits Market
https://exactitudeconsultancy.com/reports/74920/mycobacterium-tuberculosis-pcr-detection-kits-market

Mycobacterium Infections Treatment Market
https://exactitudeconsultancy.com/reports/66544/mycobacterium-infections-treatment-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.